A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
A phase 2 trial of Intismeran autogene, Pembrolizumab in renal cell carcinoma, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
Overview
A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004). is a phase 2 interventional study registered as NCT06307431 by Merck Sharp & Dohme LLC, with 272 participants planned, started 2024-04-10 and due to reach its primary completion in 2028-01-08. Interventions recorded: Intismeran autogene, Pembrolizumab, Placebo. Conditions listed: Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
Shares Intismeran autogene, Merck & Co. (MSD), Pembrolizumab.
- TrialA Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (
Shares Intismeran autogene, Merck & Co. (MSD), Pembrolizumab.
- TrialA Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
Shares Intismeran autogene, Merck & Co. (MSD), Pembrolizumab.
- TrialA Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
Shares Intismeran autogene, Merck & Co. (MSD).
- TrialA Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
Shares Intismeran autogene, Merck & Co. (MSD), Pembrolizumab.
- TrialA Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I
Shares Intismeran autogene, Merck & Co. (MSD).
- TrialA Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrol
Shares Merck & Co. (MSD), Renal cell carcinoma, Pembrolizumab.
- TrialA Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Shares Intismeran autogene, Merck & Co. (MSD), Pembrolizumab.